ArticleEuropean journal of nuclear medicine and molecular imaging2021
Kinetic analysis and optimisation of
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03995888 (A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- True-PositiveJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Safety, Biodistribution, and Radiation Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation.Frontiers in oncology · 2025Article
- Determining the optimal pharmacokinetic modelling and simplified quantification method of [European journal of nuclear medicine and molecular imaging · 2024Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?Theranostics · 2024Article
- Flotufolastat F 18: Diagnostic First Approval.Molecular diagnosis & therapy · 2023Review
- Diagnostic Performance and Safety ofThe Journal of urology · 2023Article
- Radiolabeled PSMA Inhibitors.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis phase 1 open-label study evaluated the uptake kinetics of a novel theranostic PET radiopharmaceutical,
methodsNine men, three with high-risk localised prostate cancer, three with treatment-naïve hormone-sensitive metastatic disease and three with castration-resistant metastatic disease, underwent dynamic 45-min PET scanning of a target area immediately post-injection of 300 MBq
resultsAltogether, 44 lesions from the target area were identified. Optimal visual lesion detection started 60 min post-injection. The
conclusion
trial registrationNCT03995888 (24 June 2019).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.